Should you buy CytomX Therapeutics (CTMX)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
- Implausible Analyst Target Flag→Stable
- Momentum Pullback Not Breakdown→Stable
- Quality Floor Exit Signal→Stable
- +2 more pillars — see the Why tab for full reasoning
→ Full pillar scorecard with all 5 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Implausible Analyst Target Flag
Trip ifNo plausible analyst target is established within 2 quarterly refreshes, with the ratio to price staying above 2x, or the technical take-profit target is missed by more than 20%.
- P2Momentum Pullback Not Breakdown
Trip ifThe 200-day moving average slope falls below 0% over the next 30 days, or price fails to reclaim the 200-day moving average within 2 quarters.
- P3Quality Floor Exit Signal
Trip ifThe quality score stays below 2.5 at the next quarterly refresh, confirming the exit signal remains valid.
- P4Severe Cash Burn Risk
Trip ifCash burn rate falls below -150% of revenue, or the company announces a dilutive capital raise within the next 2 quarters.
- P5Short Interest Upside Exhausted
Trip ifShort interest rises above 25% of float while calculated upside remains at or below 0% for 2 consecutive quarterly refreshes.
How the engine reached this verdict
TrendMatrix's engine output for CytomX Therapeutics, Inc. (CTMX) is SELL_IF_HOLDING with high conviction, score 3.7/10 at $3.81. An L1 hard-floor gate blocked the positive-verdict path — Quality below minimum threshold; dimensional pillars cannot lift the engine output above the verdict floor while the L1 gate is active.
The engine's exit framework anchors to a tactical sell band near $3.81, with structural invalidation at $3.54. The asymmetric R:R against a reversal hypothesis is 0.00 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
On the bear side: Concentration risk — Pipeline: Varseta-M; DATA_ISSUE: analyst_target_implausible (raw $12.50 vs price $3.81 — ratio 3.3×). Rejected, falling back to technical TP.; Quality below floor (3.2 < 4.0). Active engine warnings: DATA_ISSUE: analyst_target_implausible (raw $12.50 vs price $3.81 — ratio 3.3×). Rejected, falling back to technical TP., Quality below floor (3.2 < 4.0).
SELL output reflects multiple gate failures; recovery requires a confluence of those gates re-clearing, not a single dimension move.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates CTMX — 10-dimension breakdown →
Bear case
- ▸Concentration risk — Pipeline: Varseta-M
- ▸DATA_ISSUE: analyst_target_implausible (raw $12.50 vs price $3.81 — ratio 3.3×). Rejected, falling back to technical TP.
- ▸Quality below floor (3.2 < 4.0)